Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US

Abstract Background The objective of this study was to describe real-world adjuvant therapy (AT) use by disease substage and assess determinants of treatment choice among patients with stage III melanoma. Methods This non-interventional retrospective study included survey responses and data from pat...

Full description

Bibliographic Details
Main Authors: Eric D. Whitman, Todor I. Totev, Shan Jiang, Wilson L. da Costa, Dmitri Grebennik, Hongjue Wang, Andra-Ecaterina Boca, Rajeev Ayyagari
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-024-12178-w